Page 23 - Cipla
Cipla plans expansion, aims to launch at least one product in US every year
In India, the company is by far the leader in the respiratory drugs segment, having a turnover of over Rs 18.93 billion
We are determined to make fearless living a habit: Cipla's Umang Vohra
'We are looking to provide end-to-end solutions in the area of disease management for Patients'
 "We are determined to make fearless living a habit: Cipla's Umang Vohra")
Cipla nears its 52-week high post Q1 results
The stock has rallied 4.6% to Rs 662 on the BSE in early morning trade, trading close to its 52-week high of Rs 663 touched on November 11, 2017.
 "Cipla nears its 52-week high post Q1 results")
Cipla plans acquisitions to enter new therapies, boost Africa business
The company is looking at inorganic growth opportunities to offset delays in product approvals
 "Cipla plans acquisitions to enter new therapies, boost Africa business")
Cipla acquires 100% stake in South African pharmaceutical company Mirren
The transaction is subject to the approval by the Competition Commission of South Africa
Cipla gains 3% post USFDA approval for its generic HIV drug
The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017.
 "Cipla gains 3% post USFDA approval for its generic HIV drug")
Cipla surges 7% post March quarter results
The stock surged 7% to Rs 563, bouncing back 8% from its early morning low of Rs 520 on the BSE.
Cipla arm recalls multiple lots of antidepressant drug from US market
The report, however, did not mention the quantity of the product
 "Cipla arm recalls multiple lots of antidepressant drug from US market")
Cipla stock: Healthy momentum in sales indicates strong earnings visibility
Cipla's relatively late entry into the US market is proving a blessing
 "Cipla stock: Healthy momentum in sales indicates strong earnings visibility")
Cipla rebounds after clarification on USFDA observations for Goa unit
The stock moved higher to Rs 558, bouncing back 7% from its early morning low of Rs 523 on the BSE.
Pricing woes force Cipla, Glenmark, Lupin to go slow on US drug pipeline
Companies to focus on complex products as tough competition in generics, customer consolidation impact profits
 "Pricing woes force Cipla, Glenmark, Lupin to go slow on US drug pipeline")
Cipla gains 7% on healthy operational performance in Q3
The stock surged 7% to Rs 608 after the EBITDA margins in December quarter improved to 20.9% from 18.6% in year ago quarter and 19.7% in previous quarter.
Cipla stands out in a gloomy sector as revenue swells 15% to Rs 16 bn
Improving prospects of US business to drive the company's earnings
 "Cipla stands out in a gloomy sector as revenue swells 15% to Rs 16 bn")
Business for posterity
Companies must create value through transformational impact on the planet
Cipla battles perceptions in a new campaign
The pharma major engages directly with patients, addresses social stigma and environmental concerns to expand the brand footprint in respiratory diseases
 "Cipla battles perceptions in a new campaign")
Cipla shines in gloomy pharma pack, biggest beneficiary of faster approvals
A low base in the US also means lower risks of price erosion, but as the company builds up its product pipeline expect earnings to improve
Cipla gets USFDA nod to market generic version of cancer drug Dacogen
It is indicated for treatment of patients with myelodysplastic syndromes
Cipla's US sales get boost with limited competition drugs
In Oct, it received the nod for a generic version of limited competition drug Renvela, used to treat kidney disease
Cipla gains 3% on final approval for generic Pulmicort Respules
The company has received final approval from the USFDA to market a generic version of Astrazeneca's Pulmicort Respules.
 "Cipla gains 3% on final approval for generic Pulmicort Respules")
Cipla's consistent margin gains stand out
Sales growth, benefits from operating leverage led to an in-line performance